To investigate the influence of the intensity of coagulation spots on retinal function and the clinical course after panretinal argon laser photocoagulation in diabetic retinopathy, we conducted a prospective study in 24 eyes of 12 diabetics. One eye was treated with moderate spots (average: 300 mW), the fellow eye was coagulated with intense spots (average: 600 mW). The spot size was identical in both eyes. Subjective parameters (visual acuity, perimetry), as well as objective functions (ERG, EOG) and the clinical course, were studied preoperatively and on a regular base with a follow-up of 12 months. Visual acuity and fundus findings deteriorated less often in eyes coagulated with intense spots. Visual field loss, however, was more prevalent in eyes treated with intense spots. Early treatment complications only occurred with high-energy coagulation. For this reason, high-energy spots should not be used even though they might be indicated theoretically.

Keywords:
Diabetic retinopathy, Argon laser photocoagulation, High-energy coagulation, Randomized clinical trial, Electroretinography, Electro-oculography
This content is only available via PDF.
© 1991 S. Karger AG, Basel
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.